Sellas Life Sciences Group (SLS) said Tuesday that it has met all primary endpoints in its mid-stage trial of SLS009, a CDK9 inhibitor, in patients with relapsed or refractory acute myeloid leukemia.
The mid-stage clinical trial of SLS009 is a study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine at two dose levels of 45 and 60 milligrams.
CDK9 is a cancer target whose activity has been shown to correlate negatively with overall survival in several cancer types.
The trial met its primary endpoint of overall response rate of at least 20%, as well as key secondary endpoints of overall survival, safety, and tolerability with strong anti-tumor activity, the company said.
Sellas said it now plans to advance SLS009 into a randomized trial that will expand into the newly diagnosed AML populations, potentially supporting a New Drug Application. Trial preparation is underway, with enrollment expected to begin by Q1.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.